Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Shares Up By 25% On Pipeline Progress
Executive Summary
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.
You may also be interested in...
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
Novo Nordisk’s Obesity Drug Activities Break UK Rules Again
The company has been found in breach of the UK code once again for its work with pharmacists, although this time Novo Nordisk has escaped the heaviest censure.